Investigational Drug Information for REL-1017
✉ Email this page to a colleague
What is the development status for investigational drug REL-1017?
REL-1017 is an investigational drug.
There have been 9 clinical trials for REL-1017.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 4th 2020.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Relmada Therapeutics, Inc., Syneos Health, and Clinical Trial Unit Ente Ospedaliero Cantonale.
There are six hundred and thirty-six US patents protecting this investigational drug and zero international patents.
Summary for REL-1017
| US Patents | 636 |
| International Patents | 12,588 |
| US Patent Applications | 3,083 |
| WIPO Patent Applications | 3,639 |
| Japanese Patent Applications | 55 |
| Clinical Trial Progress | Phase 2 (2020-12-04) |
| Vendors | 7 |
Recent Clinical Trials for REL-1017
| Title | Sponsor | Phase |
|---|---|---|
| Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD | Relmada Therapeutics, Inc. | Phase 3 |
| A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) | Relmada Therapeutics, Inc. | Phase 3 |
| Open Label Study to Assess the Safety of REL-1017 for Major Depressive Disorder | Relmada Therapeutics, Inc. | Phase 3 |
Clinical Trial Summary for REL-1017
Top disease conditions for REL-1017
Top clinical trial sponsors for REL-1017
US Patents for REL-1017
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| REL-1017 | ⤷ Subscribe | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | ⤷ Subscribe |
| REL-1017 | ⤷ Subscribe | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | Capella Therapeutics, Inc. (San Diego, CA) | ⤷ Subscribe |
| REL-1017 | ⤷ Subscribe | Inhalable pharmaceutical compositions | iCeutica Pty Ltd. (Iluka, WA, AU) | ⤷ Subscribe |
| REL-1017 | ⤷ Subscribe | Powder filling processes | Adamis Pharmaceuticals Corporation (San Diego, CA) | ⤷ Subscribe |
| REL-1017 | ⤷ Subscribe | 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides | Pfizer Inc. (New York, NY) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for REL-1017
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| REL-1017 | Australia | AU2012222348 | 2031-03-01 | ⤷ Subscribe |
| REL-1017 | Australia | AU2012222351 | 2031-03-01 | ⤷ Subscribe |
| REL-1017 | Australia | AU2013224959 | 2031-03-01 | ⤷ Subscribe |
| REL-1017 | Australia | AU2013224960 | 2031-03-01 | ⤷ Subscribe |
| REL-1017 | Australia | AU2014314055 | 2031-03-01 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
